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In this study, in vitro antidermatophytic activity against Trichophyton mentagrophytes, Trichophyton rubrum, Microsporum canis,
and Microsporum gypseum was studied by disk diffusion test and assessment of minimum inhibitory concentration (MIC) using
CLSI broth macrodilution method (M38-A2). Moreover, antileishmanial and cytotoxicity activity of B. vulgaris and berberine
against promastigotes of Leishmania major and Leishmania tropica were evaluated by colorimetric MTT assay. The findings
indicated that the various extracts of B. vulgaris particularly berberine showed high potential antidermatophytic against pathogenic
dermatophytes tested with MIC values varying from 0.125 to >4mg/mL. The results revealed that B. vulgaris extracts as well as
berberine were effective in inhibiting L. major and L. tropica promastigotes growth in a dose-dependent manner with IC
50
(50%
inhibitory concentration) values varying from 2.1 to 26.6𝜇g/mL. Moreover, it could be observed that berberine as compared with
B. vulgaris exhibited more cytotoxicity against murine macrophages with CC
50
(cytotoxicity concentration for 50% of cells) values
varying from 27.3 to 362.6 𝜇g/mL. Results of this investigation were the first step in the search for new antidermatophytic and
antileishmanial drugs. However, further works are required to evaluate exact effect of these extracts in animal models as well as
volunteer human subjects.
1. Introduction
Dermatophytosis is a common contagious disease caused by
a fungus known as dermatophytes. Dermatophytes belong to
three genera of Trichophyton, Microsporum, and Epidermo-
phyton, which are able to break downkeratin in tissues such as
epidermis, hair, nails, feathers, horns, and hooves. There are
various forms of this disease including tinea corporis, tinea
pedis, tinea capitis, tinea barbae, tinea cruris, tinea manuum,
and onychomycosis [1]. At present, there are several anti-
dermatophyte drugs such as imidazoles and terbinafine for
topical treatment and triazoles, griseofulvin, and terbinafine
as oral antifungal for systemic treatment of dermatophytosis
which have shown some problems including high toxicity,
fungal resistance, and prolonged systemic therapy [1–3].
These factors express urgent needs for development of new
effective treatment alternatives. Leishmaniasis is caused by
parasitic protozoa of the genus of Leishmania transmitted by
bites of phlebotomine sand flies [4]. It is still considered a
major health problem in tropical and subtropical countries
worldwide and its clinical symptoms are varied, ranging
from simple cutaneous lesion to fatal disease [4, 5]. In
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Iran, both epidemiological forms of cutaneous leishmaniasis
(CL) are present, Anthroponotic CL (ACL) and zoonotic
CL (ZCL) caused by Leishmania tropica and Leishmania
major, respectively [5, 6]. First choice treatment drugs,
which are antimonials such as meglumine antimoniate and
sodium stibogluconate, have limitations for being used due
to the prolonged duration of treatment, high toxicity, and
high emergence of resistant parasites against these drugs
[7–9]. These factors render development of new effective
antileishmanial drugs as a requirement. Since a long time ago,
medicinal plants and their compounds have been important
and valuable sources for treatment and prevention of dis-
eases [10]. Barberry, Berberis vulgaris (family Berberidaceae),
grows in Asia and Europe. B. vulgaris called “Zereshk” in
Persian is native to south-east of Iran. Different parts of
this plant including root, leaf, bark, and fruit have been
widely used as folk medicine for treatment and prevention
of various diseases including cardiovascular, gastrointestinal,
respiratory, skin, renal, and infectious ones [11]. Previous
studies have been carried out on chemical composition of
B. vulgaris and shown that the most important constituents
of this plant are isoquinoline alkaloids such as berbamine,
palmatine, and particularly berberine [12, 13]. So far, various
studies have demonstrated antibacterial and antiparasitic
effects of this plant against several pathogenic strains due to
having berberine [14–17]. Moreover, antifungal effect of B.
vulgaris and its main component, berberine, against candida
spp. has been discovered in some investigations [18, 19]. In
the present study, the in vitro antidermatophyte, antileish-
manial, and cytotoxicity activities of various extracts of B.
vulgaris and its active principle, berberine, were described
against Trichophyton mentagrophytes, Trichophyton rubrum,
Microsporum canis, andMicrosporum gypseum as pathogenic
dermatophyte strains and Leishmania major and Leishmania
tropica as parasitic.
2. Materials and Methods
2.1. Chemicals. MTT powder [3-(4.5-dimethylthiazol-2-yl)-
2.5-diphenyl tetrazolium bromide], fetal calf serum (FCS),
and RPMI-1640 medium with L-glutamine and sabouraud
dextrose broth (SDA) were purchased from Sigma-Aldrich,
(St. Louis,MO,USA).Meglumine antimoniate (MA, Glucan-
time) as a control drug in the evaluation of antileishmanial
effects was prepared from Rhoˆne, Poulenc, France. Penicillin
and streptomycin were obtained from Alborz Pharmacy,
Karaj, Iran, and were stored at room temperature (25∘C) until
testing. Also, potato dextrose agar (PDA) was prepared from
Oxoid, Basingstoke, Hampshire, United Kingdom. All the
other chemicals and solvents were of analytical grade.
2.2. Dermatophyte Strains. Standard strains of T. mentagro-
phytes (PTCC5054),T. rubrum (PTCC5143),M. canis (PTCC
5069), andM. gypseum (PTCC 5070) were obtained from the
center for Persian Type Culture Collection (Tehran, Iran) and
were incubated in Sabouraud dextrose agar (SDA) at 30∘C for
7−10 days.
2.3. Parasite Strains. Standard strains of L. major (MRHO/
IR/75/ER) and L. tropica (MHOM/IR/2002/Mash2) were
obtained from the Center for Research and Training in
Skin Diseases and Leprosy (Tehran, Iran). The parasite
was cultured in NNN medium, subcultured in RPMI-1640,
supplemented with penicillin (200 IU/mL), streptomycin
(100 𝜇g/mL), and 15% heat-inactivated fetal calf serum (FCS).
2.4. Preparation of Extracts
2.4.1. Plant Collection and Authentication. The B. vulgaris
root due to having the high percentage of berberine [11]
was collected from the farms in the Baft district of Kerman
province, Iran, in May 2012. The identities were confirmed
by the botanist at the Botany Department of Shahid Bahonar
University, Kerman, Iran. Voucher specimen (kf585) of the
plant materials was deposited at the Herbarium of Depart-
ment of Pharmacognosy of the School of Pharmacy, Kerman
University of Medical Science, Kerman, Iran.
2.4.2. Obtaining the Aqueous Extract. Fifty grams of plant
material were ground and boiled gently with 500mL distilled
water for approximately 1 h. The filtered aqueous extracts
were concentrated in a rotary vacuum evaporator and dried
by exposure to hot air to yield solid material and then were
stored at −20∘C until testing.
2.4.3. Preparation of the Methanolic and Chloroform
Extracts. The dried plant materials (500 g) were grounded
and extracted by percolation method by chloroform and
methanol successively for 72 h in room temperature. Solvents
were removed in a rotary evaporator and extracts were
concentrated to dryness and stored at −20∘C until testing.
The B. vulgaris root yielded 29.2%, 25.1%, and 27.6% aqueous,
chloroform, and methanolic extract of dried plant materials.
2.4.4. Preparing of the Berberine. Berberine (2,3-methyl-
enedioxy-9,10-dimethoxyprotoberberine chloride) as main
compound of B. vulgaris was prepared from Sigma-Aldrich,
(St. Louis, MO, USA) and dissolved in the dimethyl sulfoxide
(DMSO). Final concentration of DMSO never exceeded 1%
either in control or treated samples.
2.5. Preparing Peritoneal Macrophage Cells. In order to
investigate cytotoxicity activity of B. vulgaris and berberine,
peritoneal macrophages were collected from male healthy
BALB/c mice (4–8 weeks old) by injecting 2–5mL of cold
RPMI-1640 medium into mouse peritoneal cavity. Then, the
aspirated macrophages were washed twice and resuspended
in RPMI-1640medium.The experimental procedures carried
out in this survey were in compliance with Standard Guide-
lines of Kerman University of Medical Sciences (Kerman,
Iran) for Care and Use of Laboratory Animals.
In this investigation, antidermatophytic activities of vari-
ous extracts of B. vulgaris and itsmain constituent, berberine,
were evaluated by disk diffusion method and also minimum
inhibitory concentration (MIC) was determined using broth
macrodilution method.
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2.6. Disk Diffusion Method. To assess antidermatophytic
activity of B. vulgaris and berberine by disk diffusion
method, fresh cultures of T. mentagrophytes, T. rubrum,
M. canis, and M. gypseum after 3 weeks were spread on
SDA. Then, filter paper disks (0.5 cm) were loaded with
1mg/disk of various extracts of B. vulgaris (1mg/disk) and
berberine (0.01mg/disk). Also, ketoconazole (0.01mg/disk)
and dimethyl sulfoxide (DMSO 1%), methanol, and water
were used as positive andnegative controls, respectively. After
evaporation of the solvents, the disks were placed on the
SDA plates. They were incubated at 30∘C for 7–14 days and
were measured for the developing diameter of inhibition
zones around the disks. Finally, inhibition zone diameter was
measured and the results were recorded. All the experiments
were repeated in triplicate.
2.7. Determining Minimum Inhibitory Concentration (MIC).
TheMIC determination of various extracts of B. vulgaris and-
berberine was carried out by broth macrodilution method,
according to M38-A2 protocol of Clinical and Laboratory
Standards Institute (CLSI) for filamentous fungi with some
modifications [20]. At first, dermatophyte strains were sub-
cultured on PDA slants and incubated at 30∘C for 7 to 10
days. Mature colonies were covered with 2mL of sterile
physiological saline (0.85%), suspensions were prepared by
gently probing the colony with the tip of a sterile Pasteur
pipette and transferred to a sterile conical tube, and the
final volumewas adjusted to 5mL with saline. The resulting
mixture of conidia and hyphal was vortex mixed for 15 sec
and the heavy particles were allowed to settle for 5–10min.
The upper homogeneous suspension was used for further
testing. The resulting suspension was counted in a Neubauer
chamber and standardized to concentrations of 1 × 105 to 5
× 105 cfu/mL. This suspension was further diluted 1 : 10 with
RPMI-1640 medium broth with L-glutamine and without
sodium bicarbonate to final concentrations of 1 × 104 to 5
× 104 cfu/mL. For the broth macrodilution method, 0.9mL
of the final conidia suspensions was mixed with 0.1mL
of various concentrations of extracts of B. vulgaris (0.25–
4mg/mL) andberberine (0.062–0.5mg/mL) in test tubes and
incubated at 30∘C for seven days. The positive control tube
contained 0.9mLof conidial suspension and 0.1mL of RPMI-
1640 and the negative one only contained 1mL of RPMI-1640.
The minimum concentrations at which no visible growth
was observed were defined as MIC, which were expressed in
mg/mL.
2.8. Antileishmanial Activity. Antileishmanial activity of B.
vulgaris extracts and berberine was evaluated on promastig-
ote stages of L. major and L. tropica by colorimetric cell
viability (MTT) assay using the method described by Shokri
et al. [21]. Briefly, 100 𝜇L of the promastigotes (106 cells/mL)
harvested from logarithmic growth phase was added to a 96-
well microtiter plate.Then, 100 𝜇L of different concentrations
(0–200𝜇g/mL) of each plant extract was added to each well
and incubated at 37∘C ± 1∘C for 72 h. After incubation with
the extracts, 10 𝜇L of MTT solution (5mg/mL) was added to
each well and incubated at 37∘C for 4 h. The promastigotes
were cultured in the complete medium with no drug used
as positive control and with no promastigotes and drugs as
blank. Finally, absorbance was measured by an ELISA reader
(BioTek-ELX800) at 490 nm. 50% inhibitory concentrations
(IC
50
values) were also calculated by Probit test in SPSS
software.
2.9. Cytotoxicity Activity. In order to evaluate cytotoxic
activity on peritoneal macrophage cells, CC
50
(cytotoxicity
concentration for 50% of cells) of various extracts of B.
vulgaris and berberine on peritoneal murine macrophages
were determined. The macrophage cells were plated at 106
cells/mL in 96-well Lab-Tek (Nunc, USA) and left to adhere
for 2 h at 37∘C in 5% CO
2
. Nonadherent cells were removed
by washing with medium after 2 h of incubation in similar
conditions. In the next step, 190𝜇L of complete RPMI
medium was added to each well and later 10 𝜇L of dilutions
of the extracts (previously prepared in medium) was added.
The macrophages were treated with the extracts from 10 to
500𝜇g/mL for 72 h [22].The cytotoxicity was evaluated using
the colorimetric assay with MTT as described previously in
the promastigote assay.
2.10. Statistical Analyses. In this work, all the experiments
were repeated in triplicate. SPSS software, Version 17, (SPSS
Inc., Chicago) was used for data entry and statistical analysis
and differences between the groups were determined using





values of the groups, 𝑡-test was per-
formed. 𝑃 value of less than 0.05 was considered statistically
significant. The selectivity index (SI) calculated based on the
equation of CC
50
for peritoneal macrophage cells/IC
50
for
promastigote forms of both species of Leishmania was used
to compare toxicity and activity of the crude extracts and
berberine, as described by Weniger et al. [23].
3. Results
3.1. Antidermatophytic Activity. In evaluating antidermato-
phytic effects of various extracts of B. vulgaris andberberine
by disk diffusion method, it could be observed that all the
aforementioned extracts and berberine had potent antider-
matophytic effects against T. mentagrophytes, T. rubrum, M.
canis, and M. gypseum as pathogenic dermatophyte strains
(Table 1). Berberine was much more effective than various
extracts ofB. vulgaris once it exhibitedwider zone diameter of
inhibition (>50mm) for all the tested dermatophyte strains.
Moreover, among the tested extracts of B. vulgaris, methanol
extract showed higher antidermatophytic effects (from 26.3
to 37.6mm) than chloroform (from 24.3 to 32mm) and
aqueous extracts while the lowest antidermatophytic effect
was related to aqueous extract (from 18.3 to 25.3mm) of B.
vulgaris. The present results revealed that M. canis and T.
mentagrophytes were the most sensitive and resistant strains
to various extracts of B. vulgaris and berberine, respectively.
It should bementioned that negative controls were not shown
any inhibition zone against the tested dermatophte strains.
Table 2 demonstrates results of MIC values of different
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Table 1: Antidermatophytic effects of various extracts of B. vulgaris and its main constituent, berberine, against T. mentagrophytes, T. rubrum,
M. canis, andM. gypseum by disk diffusion method. Data are expressed as the mean ± SD (𝑛 = 3).
Dermatophytes Zone of inhibition (mm)
Chloroform extract Methanolic extract Aqueous extract Berberine Ketoconazole
T. mentagrophytes 24.3 ± 2.15 26.3 ± 1.52 18.3 ± 1.17 51.6 ± 3.08 28.6 ± 1.17
T. rubrum 25.3 ± 2.15 28.6 ± 2.08 21.6 ± 2.15 55 ± 3.08 30.3 ± 2.52
M. canis 32 ± 2.5 37.6 ± 3.08 25.3 ± 2.52 >60 37.6 ± 1.52
M. gypseum 27.6 ± 1.17 30.6 ± 1.52 23.3 ± 1.17 >60 31.6 ± 1.52
Table 2: Minimum inhibitory concentration (MIC) of various extractsof B. vulgaris and its main component, berberine, against T.
mentagrophytes, T. rubrum, M. canis, andM. gypseum by broth macrodillution method.
Dermatophytes MIC (mg/mL)
Chloroform extract Methanolic extract Aqueous extract Berberine Ketoconazole
T. mentagrophytes 4 4 >4 0.250 0.250
T. rubrum 4 2 4 0.125 0.250
M. canis 2 1 2 0.062 0.125
M. gypseum 4 1 4 0.125 0.250
extracts of B. vulgaris and berberine by broth macrodilution
method. It could be seen that MIC values similar to disk
diffusion method confirmed that berberine had more anti-
dermatophytic effects than various extracts ofB. vulgariswith
the lowest MIC values for all the tested dermatophyte strains.
3.2. Antileishmanial Activity. In the investigation of antileish-
manial effects of B. vulgaris extracts and berberine using
MTT assay, it could be seen that various extracts of B.
vulgaris, particularly berberine,significantly (𝑃 < 0.05)
suppressed growth rate of promastigotes in both strains
based on a dose-dependent response. Berberine indicated
much higher activity against promastigote forms than crude
extracts of B. vulgaris. Similarly, methanolic extract wasmore
effective in inhibiting promastigotes growth than aqueous
and chloroformextracts of B. vulgaris. Aqueous extract also
revealed the lowest antileishmanial activity against these
parasitic forms. The measured IC
50
values forberberine were
2.1 𝜇g/mL and 2.9 𝜇g/mL against promastigote forms of L.
major and L. tropica, respectively. While the measured IC
50
values for various extracts of B. vulgaris and MA as control
drug against promastigote forms of L. major and L. tropica
were higher than berberine (Table 3).
3.3. Cytotoxicity Activity. Crude extracts of B. vulgaris
showed no significant cytotoxicity on peritoneal macrophage
cells while berberine as the active constituent displayed a
more cytotoxicity effect at high concentrations ≥25 𝜇g/mL
on peritoneal macrophages. The CC
50
values for different
extracts of B. vulgaris and also berberine against peritoneal
macrophage cells and selectivity index (SI) are shown in
Table 4.
4. Discussion
Since ancient times, plant-derived compounds and plant
extracts have been used as a valuable natural resource of
Table 3: IC50 values of various extracts of B. vulgaris and berberine
against the growth rate of promastigote forms of Leishmaniamajor
and Leishmania tropica. Data are expressed as the mean ± SD (𝑛 =
3).
Sample IC50 value (𝜇g/mL)
a
L. major L. tropica
Methanolic extract 12.8 ± 1.17 16.1 ± 1.15
Aqueous extract 22.3 ± 2.51 26.6 ± 2.51
Chloroform extract 19.6 ± 2.08 23.3 ± 2.15
Berberine 2.1 ± 0.05 2.9 ± 0.05
MAb 8.2 ± 1.15 11.6 ± 0.05
aConcentration of drug that caused 50% of growth inhibition of promastig-
otes.
bMeglumine antimoniate (Glucantime) as control drug.
Table 4: CC50 values of methanolic and aqueous extracts of B. vul-
garis and berberine on peritoneal macrophage cells and selectivity
index (SI) against promastigote forms of L. major and L. tropica.
Data are expressed as the mean ± SD (𝑛 = 3).
Samples CC50
a
± SD (𝜇g/mL) SI
b
L. major L. tropica
Methanolic extract 203.3 ± 3.08 15.9 12.6
Aqueous extract 362.6 ± 4.6 16.3 13.8
Chloroform extract 297.6 ± 4.6 15.2 12.8
Berberine 27.3 ± 2.08 13 9.4
aConcentration of extracts that caused 50% mortality in BALB/c mice
peritoneal macrophages.
bSelectivity index (CC50/IC50).
traditional remedy [24]. In the past decades, advent of
synthetic antimicrobial drugs has caused reluctance in plants
as a rich source of antimicrobial agents [25]. However, in
recent years, emergence of some limitations in the use of
these drugs has caused change in situation and interest in
the field of ethnobotanical research [26]. In the present
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study, high potential B. vulgaris extracts and especially its
active principle, berberine, were demonstrated as a natural
source for the production of new antidermatophytic and
antileishmanial drugs on an in vitro model. As mentioned,
based on the previous studies, the highest biological activity
of the B. vulgaris was due tohaving isoquinoline alkaloids
such as berberine. This alkaloid is sparingly soluble in water
and it is expected that the liquid extraction contains negligible
amounts of berberine, whereas methanolic extract can draw
this alkaloid from plant roots. In the case of antifungal effects
of berberine, there are few studies that approve high potential
of berberine against some pathogenic fungal strains. One
such study was conducted by Freile et al. [14] indicating
that berberine had potent antifungal effects against different
Candida spp. with MIC values varying from 16 to 128 𝜇g/mL.
Furthermore, Ghaderi and Maleki Nejad [18] showed that B.
vulgaris extracts had significant anticandidal effects, which
were more prominent for methanolic extracts. Also, these
researchers reported that anticandidal activity of B. vulgaris
might be due to the presence of several bioactive compounds,
especially berberine.The mechanism underlying antifungal
activities of berberine is not fully understood. However, Park
et al. [27] exhibited that inhibitory effect of berberine on
growth of Candida was probably due to inhibition of both
sterol and cell wall biosyntheses in this fungus. Previous
researches have reported that berberine has a synergistic
effect in combinationwith amphotericin B in the treatment of
candidiasis inmice, and it combined with fluconazole against
clinical isolates of Candida albicans resistant to fluconazole
[19, 28]. Therefore, all of these results are consistent with
results of the present study.
So far, in various investigations, antiparasitic effects of B.
vulgaris and its bioactive compounds (particularly berberine)
against some pathogenic parasite strains have been reported.
The study conducted byKaneda et al. [16] showed that berber-
ine significantly reduced growth of Entamoeba histolytica,
Giardia lamblia, and Trichomonas vaginalis on an in vitro
model and caused morphological changes in their structure.
Also, Sheng et al. [29] reported that, in chloroquine resistant
malaria, the combination of berberine and pyrimethamine
had a synergistic effect in the elimination of parasites and
it was more effective than other drugs such as tetracycline
or cotrimoxazole. In another survey, Vennerstrom et al.
[17] demonstrated that berberine derivatives significantly
suppressed the parasite load in liver or ulcer size in golden
hamsters infected with Leishmania donovani and Leishmania
braziliensis when compared with meglumine antimoniate.
Fata et al. [15] also found that ethanolic extract of B. vulgaris
significantly decreased ulcer size of cutaneous leishmaniasis
of BALB/c mice after 2 weeks. Recently, Rouhani et al. [30]
reported that aqueous extract of B. vulgaris fruits had an
effective scolicidal activity at low concentration (4mg/mL)
and short exposure time (5min). Thus, the present results
were in agreement with those of previous studies in demon-
strating antiparasitic activities of B. vulgaris and its bioactive
compound, berberine.
In this survey, it was indicated that various extract-
sof B. vulgaris had no significant cytotoxicity effect at
low concentrations in peritoneal macrophage cells while
berberine indicated moderate cytotoxicity effects on peri-
toneal macrophage cells. Similar to these findings, Peychev
[31] revealed that oral administration of B. vulgariswas mod-
erately toxic in mice (LD
50
= 2.6 ± 0.22 g/kg b.w). In contrast,
Lin et al. [32] showed that berberine had strong inhibitory
effect on proliferation of both hepatoma and leukemia cell
lines on in vitro model. However, it has been proven that
berberine is not considered toxic at the doses used in clinical
situations nor has it been shown to be cytotoxic ormutagenic;
however, some side-effects have been mentioned to result
from high dosages [11]. In addition, SIs ≥ 10 of extracts
showed their safety to the macrophages and specificity to
the parasite [23]. Thus, it could be proposed that B. vulgaris
extracts were safe for mammalian cells considering that at
high concentrations, they showed significant cytotoxicity in
the host cells.
5. Conclusion
To conclude, findings of this study could provide the first step
in the search for new antidermatophytic and antileishmanial
drugs and aid the use of B. vulgaris in folk medicine for
dermatophytic and leishmaniasis infections. In addition,
further studies are required to elucidate the exact effects of
these extracts and berberine in animal models as well as
volunteer human subjects as a new therapeutic agent.
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